Abstract: A pharmaceutical composition comprising: (a) a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; R2 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; and R3 is hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, or O—C1-4-alkylene-COO—C1-4-alkyl, or an enantiomer, mixture of enantiomers, or racemate thereof, or an acid addition salt with pharmacologically acceptable acids thereof, or a solvate or hydrate thereof; and (b) another active substance 2, wherein the molar ratio of the compound of formula 1 to the active substance 2 is 1:10 to 12:1.

Abstract: The present invention related to the use of a pharmaceutical composition which is essentially free of pharmaceutically active ingredients for the treatment of human skin, especially in the treatment of rosacea, acne, atopic dermatitis, contact dermatitis, perioral dermatitis, psoriasis or neurodermitis, as well as for prophylactic and/or cosmetic purposes.

Abstract: A waterless foamable carrier and pharmaceutical composition which is suitable for external and internal administration is disclosed. The composition is single phase and includes at least one liquid oil; and a glyceride. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.

Abstract: An oromucosal formulation containing as an active ingredient a substituted imidazole derivative of formula (I) where Y is —CH2— or —CO—, R1 is halogen or hydroxy, R2 is H or halogen and R3 is H or lower alkyl, or an acid addition salt of this imidazole derivative, and a process for its preparation.

Abstract: Viral upper respiratory tract infections, upper respiratory infections, and common colds can be effectively treated by the administration of a combination of a nasal steroid and a nasal antihistamine. By the administration of the combination of a nasal steroid and a nasal antihistamine with the onset of cold symptoms, the histamine cascade and the inflammatory response are impeded or eliminated, reducing the severity, duration, or frequency of the onset of cold symptoms. The combination of a nasal steroid and a nasal antihistamine may be, for example, a physical mixture of the steroid and antihistamine, or it may effectively be a combination wherein the patient is administered one component (either the steroid or the antihistamine) followed by the other, without physical mixing beforehand.

Abstract: The invention provides for the use of a disinfectant consisting of a mixture of ethanol, 1-propanol and 2-propanol, an antimicrobial, amphoteric surfactant and water for disinfection of display screen surfaces of electronic devices. Mobile communication devices, especially those which are used in the medical sector, have plastic surfaces, more particularly in the form of display screen surfaces. These cannot be disinfected with conventional alcoholic disinfectants. The disinfectant used in accordance with the invention enables effective eradication of microorganisms such as, more particularly, fungi, bacteria and yeasts, with simultaneously good material compatibility.

Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

Abstract: Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided.

Abstract: An inhalation device for administering one or more sedatives via pulmonary inhalation for treating a sleep disturbance.

Abstract: The object of the present invention is to provide a hair restorer which exhibits a stimulatory effect on hair restoration against hair loss, hair thinning, split ends, hair graying, etc., with higher stability and safety than those of known hair restorers containing 5-aminolevulinic acids as active components. By using 5-aminolevulinic acid or its salt or its derivative, and a composition containing iron sodium diethylenetriaminepentaacetate or iron ammonium diethylenetriaminepentaacetate as active components, a hair restorer and a method for restoring hair which are excellent in hair growth promotion, and stability and safety, are provided.

Abstract: Dihydronepetalactone, a minor natural constituent of the essential oil of catmints (Nepeta spp.) such as Nepeta cataria, has been identified as an effective insect repellent compound. Synthesis of dihydronepetalactone may be achieved by hydrogenation of nepetalactone, the major constituent of catmint essential oils. This compound, which also has fragrance properties, may be used commercially for its insect repellent properties, and methods for making an composition thereof are disclosed.

Abstract: A pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use. In a second embodiment, an oil-in water emulsion having a vitamin, an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.

Abstract: Described herein are emulsions and compositions for the treatment of various dermatoses. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. Also described are methods of treating dermatoses, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition. The dermatosis may be seborrheic dermatitis.

Abstract: The invention provides a method of producing a highly stable pharmaceutical aerosol suspension formulation suitable for use in a metered dose inhaler, the formulation comprising formoterol fumarate di-hydrate in suspension, a steroid in suspension, a propellant and ethanol, the method comprising the steps of drying the formoterol fumarate di-hydrate to a water content of 4.8 to 4.28%.

Abstract: Cinnamic acid-based oligomers and therapeutic uses thereof are provided. The oligomers are used as anti-inflammation agents, inhibitors of elastase and anti-oxidants, and in some cases (e.g. the treatment of lung disorders such as lung cancer) all three activities are simultaneously beneficial. Subsets of the oligomers (e.g. ?-O4 and ?-5 trimers and tetramers) are used as anticoagulants.

Abstract: Certain surfactants suitable for use alone to dissolve a water-insoluble component in compositions is described for providing VOC-free compressed gas aerosol compositions. The compositions include water-insoluble component(s), a surfactant and water. The water-insoluble component(s) can be active agent(s), such as fragrance(s) and/or an insecticide(s). The surfactant is present as a single surfactant which, in the absence of a solvent, dissolves or disperses the water-insoluble component(s) and provides a homogenous blend in water which provides a stable compressed gas emulsion.

Abstract: The present invention relates to the use of a container, made of an inorganic additive containing plastic material, for reducing physical/chemical interaction between the container and an oil, fat and/or wax containing formulation contained therein.

Abstract: Spray compositions are formulated with powders (e.g. corn starch) which improve skin feel, and also have a hydrophobically modified oxide additive (e.g. modified silica) to reduce the incidence of can/bottle clogging and sedimentation caused by the powder. The oxide is a mixed hydrophobic/hydrophilic oxide such as hydrophobicly modified fumed silica (e.g. silica dimethyl silylate). In one embodiment DEET can be delivered by such formulations.

Abstract: The present invention is antibiotic compositions, ventilator based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an in-line nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

Abstract: The invention discloses pharmaceutical compositions in the form of a dusting powder or dry spray, possessing a high absorbent capacity, painkilling activity and wound-healing action, which compositions consist of croscarmellose sodium, a non-steroidal anti-inflammatory drug (NSAID) and hyaluronic acid, and optionally also contain other pharmacologically active substances and/or excipients. The compositions disclosed herein are suitable for use in the treatment of skin lesions wherein the presence of exudate limits wound healing and causes pain; they are therefore particularly suitable for chronic ulcerous skin lesions of various origins and burns.

Abstract: A topical foam pharmaceutical composition for rectal administration comprising rifaximin is described. Also described is a method of making the composition and the use of the composition as a medicament.

Abstract: The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.

Abstract: The use of biodegradable and biocompatible lactide-based nonionic amphiphiles to stabilize a model drug (salbutamol base) dispersion in hydrofluoroalkane (HFA) propellant is disclosed. The results have industrial applicability to the development of HFA-based dispersion pressurized metered-dose inhaler formulations.

Abstract: The present invention relates to a novel propellant-gas-containing medicament composition based on tiotropium 1, processes for the preparation thereof and the use of such medicament compositions in the treatment of respiratory complaints.

Abstract: The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations.

Abstract: The present invention relates to water-in-oil aerosol emulsion compositions and related methods and, in particular, to aerosol emulsions containing an active agent. In some embodiments, the aerosol emulsion comprises a propellant dissolved in the oil phase.

Abstract: Methods and devices for creating a supersaturated liquid solution having dissolved gas with hyperbaric partial pressures and aerosolizing the supersaturated solution via a nebulizer. High partial pressures of the dissolved gas may be maintained before, during, and after the aerosolization process. Thus, the hyperbaric partial pressures may be retained in the aerosol particles even after the particles are exposed to ambient barometric pressure. The aerosolized particles may be inhaled to improve oxygenation and blood flow to the lung or alternatively, the aerosolized particles can be topically applied to accelerate wound healing. Nebulizers may produce aerosol particles in some embodiments have mass median aerodynamic diameters of between about 0.25 and about 5 microns, thereby allowing sufficient deposition in the lung parenchyma, proximal to alveoli.

Abstract: Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.

Abstract: Aerosol odor eliminating compositions are described which are aqueous based and include at least one alkylene glycol, at least one surfactant wherein one or more of the at least one surfactant has an HLB of about 7 to about 20, compressed gas propellant, at least one fragrance, a buffering system and water. The composition excludes inclusion of a low molecular weight monohydric. The compositions have a volatile organic content (VOC) of less than 5.0% of the total composition based on 100 wt. %, or alternatively, a VOC of less than 0.1% as to the total composition based on 100 wt. % in absence of the wt. % of the active fragrant material of the fragrance. The compositions additionally have a consistent spray rate at multiple pressure ranges.

Abstract: The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.

Abstract: Methods for treating bacterial respiratory tract infections in an individual comprise administering a therapeutic amount of nitrite composition having a pH of less than 7, and in specific embodiments, a pH of about 5.5-6.5, to the individual. The individual may be a pulmonary disease diagnosed individual and/or the infection may be at least in part caused by mucoid mucA mutant Pseudomonas aeruginosa.

Abstract: The invention relates to the use of an antimycotic agent and an epithelial cell or endothelial cell adhesion inhibitor for producing a combination drug for the topical treatment of Candida mycoses selected from vulvovaginal candidiasis, oropharyngeal candidiasis (oral thrush), diaper dermatitis (diaper thrush) and intertriginous (Candida) eczema.

Abstract: Disclosed herein are vials and devices containing a ketorolac solution for intranasal administration and a head space comprising no more than about 10% v/v oxygen and which vials and devices are stored in an oxygen-impermeable pouch. Also disclosed are processes for preparing the vials and devices.

Abstract: A stable, high VOC, single phase, non-aqueous liquid aerosol composition having enhanced dispersion based on reduced particle size and increased evaporation rate to result in improved active ingredient dispersion, slower settling in air and less residue on surfaces. The composition includes at least one hydrocarbon propellant, at least one active ingredient and a solvent blend. The solvent blend includes at least one low volatility solvent and at least one high volatility solvent wherein each has a defined vapor pressure and Hansen solubility parameter. The composition upon dispersion as a spray has an aerosol particle size of less than 30 microns.

Abstract: Certain surfactants suitable for use alone to dissolve a water-insoluble component in compositions is described for providing VOC-free compressed gas aerosol compositions. The compositions include water-insoluble component(s), a surfactant and water. The water-insoluble component(s) can be active agent(s), such as fragrance(s) and/or an insecticide(s). The surfactant is present as a single surfactant which, in the absence of a solvent, dissolves or disperses the water-insoluble component(s) and provides a homogenous blend in water which provides a stable compressed gas emulsion.

Abstract: Benzoic acid ester compounds of formula (I): wherein R and R1-R5 have the meanings explained in the description, methods for producing them and use thereof in cosmetic, pharmaceutical, personal care and industrial preparations as sunscreens based on photochemical precursor properties of ultraviolet absorbers.

Abstract: Disclosed herein is a cosmetic composition for the treatment of keratinous fibers, for example, human keratinous fibers, such as the hair, in the form of an aerosol comprising at least one polysaccharide of lambda-carrageenan type and carbon dioxide as propellant. Also disclosed herein is a cosmetic treatment method for keratinous fibers comprising applying such a composition to the keratinous fibers.

Abstract: Described herein are cyclodextrin-stabilized microemulsion systems useful for increasing the solubility, stability, bioavailability, or safety of an active agent for delivery to the skin. The microemulsions may reduce the occurrence of skin irritation or odor upon application. In certain embodiments, the active agent is substantially insoluble in water. The microemulsions may be formulated as semi-solids, for example creams, or as aerosol or non-aerosol foams. Also described are methods of treating skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive microemulsion.

Abstract: Aerosols containing a plurality of aqueous droplets, each droplet containing on average at least one essentially-neutral particle sized to fit within the droplet are provided. Aerosols wherein an active pharmaceutical ingredient is attached to, or otherwise incorporated in the essentially neutral particles are also provided. Methods for administering an active pharmaceutical ingredient to a subject in need thereof via inhalation of these aerosols, preferably via nebulizer, are also provided.

Abstract: The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen.

Abstract: A composition for treating a water system to remove scale, microorganisms and biofilm, and corrosion by-products. The composition comprises chelating agents and a surfactant. Depending on the water system being treated, the composition may be a solid dissolved by water in the system being treated or may be a pre-mixed foam or aerosol. A treatment system particularly suitable for flowing water systems comprises a container for holding such a treatment composition and mixing it with a portion of water from the water system, a filter for removing solids dislodged during treatment, and a corrosion monitor. A method for using such a treatment composition comprises draining substantially all existing water in the water system, filling or rinsing the system with fresh water, contacting the treatment composition with substantially all parts of the water system, and draining the treatment composition from the system before resuming normal operations.

Abstract: The present invention relates to compositions based on silver and hyaluronic acid and their use in the management of cutaneous lesions of various origin (acute and chronic wounds, ulcerations, burns, etc.) mainly when characterized by the presence of exudate and hence at high risk of infection.

Abstract: The present invention relates to a wool care composition comprising pyrethroid insecticide, a copolymer and a solvent wherein the said copolymer binds with the solvent and pyrethroid insecticide. This composition can be an improved aerosol spray formulation for treating of pure or blended woollen clothing and textile, fur and feather lined garments and other keratinous items for protection or insect proofing from various types of insect pests both clothes moths and carpet beetles during their storage, transport and use. Wool care aerosol solution can be sprayed with pressurized container having either a propellant as ready-to-use aerosol or manually operated sprayers. The aerosol spray composition may also contain fragrance and solvent. The other components in the composition are at least one copolymer/emulsifier and/or dispersant.

Abstract: The invention relates to pressurized gas formulations for dosage aerosols, in which a medicament is formulated suspended in TG 227 ea (1,1,1,2,3,3,3-heptafluoropropane) and/or TG 134 a (1,1,1,2-tetrafluoroethane) as a propellant, and to their use for producing a medicament. The aerosol is preferably an inhalation aerosol.

Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.

Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: Described herein are respiratory drug condensation aerosols and methods of making and using them. Kits for delivering condensation aerosols are also described. The respiratory drug aerosols typically comprise respiratory drug condensation aerosol particles. In some variations the respiratory drug compound is selected from the group consisting of ?-adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors, asthma antagonists, anti-endothelin drugs, prostacyclin drugs, ion channel or pump inhibitors, enhancers, or modulators and pharmaceutically acceptable analogs, derivatives, and mixtures thereof. Methods of treating a respiratory ailment using the described aerosols are also described. In general, the methods typically comprise the step of administering a therapeutically effective amount of respiratory drug condensation aerosol to a person with a respiratory ailment.

Abstract: A topical foam pharmaceutical composition for rectal administration comprising rifaximin in the form of nanosized particles is described. Also described is a method of making the composition and the use of the composition to as a medicament.

Abstract: The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.